[EN] SUSTAINED-RELEASE BUPRENORPHINE FORMULATIONS BACKGROUND OF INVENTION<br/>[FR] ARRIÈRE-PLAN DE L'INVENTION DE FORMULATIONS DE BUPRÉNORPHINE À LIBÉRATION PROLONGÉE
申请人:ALAR PHARMACEUTICALS INC
公开号:WO2018050043A1
公开(公告)日:2018-03-22
An injectable pharmaceutical composition includes a solution of 3-acyl-buprenorphine, or a pharmaceutically acceptable salt thereof, in a biocompatible organic solvent, wherein the injectable pharmaceutical composition exhibits a steady release profile lasting over one week when injected into a patient. The acyl group is an alkylcarbonyl group, and an alkyl portion of the alkylcarbonyl group is a straight-chain, branched-chain, having 1-20 carbon atoms. The biocompatible organic solvent is N-methyl-2-pyrrolidone, ethyl acetate, ethanol, butanol, 2-butanol, isobutanol, ispropanol, glycerin, benzyl benzoate, dimethyl sulfoxide, N, N-dimethylacetamide, propylene glycol, dimethyl glycol, benzyl alcohol, or a combination of two or more thereof.
一种可注射的制药组合物,包括3-酰基丁丙诺啡或其药学上可接受的盐在
生物相容性有机溶剂中的溶液,其中,当注射到患者体内时,该可注射的制药组合物表现出持续释放的稳定剖面,持续时间超过一周。酰基基团是烷基羰基基团,烷基羰基基团的烷基部分是直链、支链,具有1-20个碳原子。
生物相容性有机溶剂是N-甲基-
2-吡咯烷酮、
乙酸乙酯、
乙醇、
丁醇、
2-丁醇、
异丁醇、
异丙醇、
甘油、
苯甲酸苄酯、
二甲基亚砜、N,N-二甲基乙酰胺、
丙二醇、二甲基
乙二醇、
苯甲醇或两种或两种以上的组合。